De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

Movement Disorders : Official Journal of the Movement Disorder Society
Ronald K B PearceC D Marsden

Abstract

In contrast to levodopa (L-dopa), de novo administration of the D2-like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated subhuman primates is not associated with the onset of significant dyskinesia. We now compare the ability of the novel D2-like selective dopamine agonist ropinirole with that of bromocriptine and L-dopa to induce dyskinesia in MPTP-treated common marmosets. MPTP-treated common marmosets were treated with placebo, L-dopa plus carbidopa, ropinirole, or bromocriptine daily for 30 days (n = 4 per group) in doses that were titrated to similarly increase locomotion and improve motor disability. L-dopa rapidly induced dyskinesia of moderate to severe intensity, whereas ropinirole and bromocriptine produced mild dyskinesia over the course of the study that was significantly less severe than in the L-dopa-treated group (p < 0.05). However, in a separate group of marmosets previously primed with L-dopa to exhibit dyskinesia, ropinirole administration elicited severe dyskinesias comparable with that of L-dopa in a dose-dependent fashion. Ropinirole, in common with bromocriptine, has a lesser tendency than L-dopa to produce dyskinesi...Continue Reading

References

May 1, 1992·Annals of Neurology·M R LuquinJ A Obeso
Aug 1, 1992·Experimental Neurology·B Gomez-Mancilla, P J Bédard
Mar 1, 1992·Neurochemistry International·T M EngberT N Chase
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·U K Rinne
Aug 4, 1990·Lancet·R Howard, D Castle
Aug 4, 1990·Lancet·M J VidailhetY Agid
Apr 1, 1987·Clinical Neuropharmacology·E TolosaF Forcadell
Jan 1, 1985·Neurology·H TeräväinenM Hietanen
Jan 1, 1984·Clinical Neuropharmacology·G DevathasanP K Wong
Mar 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·G FabbriniG L Lenzi
Jan 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetP J Bédard

❮ Previous
Next ❯

Citations

Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·J L MontastrucJ M Senard
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·C N HomannH P Hartung
Dec 30, 2003·BioFactors·M Flint Beal, Clifford W Shults
Oct 3, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine H O DeaneCarl E Clarke
Oct 3, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Lance A SmithPeter Jenner
Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Tamar C RubinsteinJeffrey M Hausdorff
Mar 5, 2013·Journal of Neural Transmission·K Ray ChaudhuriKapil D Sethi
Jan 4, 2008·Pharmaceutical Research·Elisabetta EspositoRita Cortesi
May 11, 2005·Neurobiology of Disease·Diane T StephensonMarina E Emborg
Dec 13, 2000·Pharmacology, Biochemistry, and Behavior·K FukuzakiR Nagata
Feb 23, 2000·Pharmacology, Biochemistry, and Behavior·K FukuzakiR Nagata
Nov 14, 2002·Neurotoxicology·Donato A Di MonteAmy B Manning-Bog
Feb 13, 2003·Journal of Neuroscience Methods·Fang BaChristina G Benishin
Sep 5, 2001·Neurologic Clinics·J E Ahlskog
Sep 29, 2000·Parkinsonism & Related Disorders·A Lledó
Sep 29, 2000·Parkinsonism & Related Disorders·T Kondo
Jun 1, 2002·Parkinsonism & Related Disorders·J ZhangG Perry
Aug 14, 2003·Parkinsonism & Related Disorders·Fabrizio Stocchi
Jul 2, 2008·Parkinsonism & Related Disorders·Z K Wszolek, K Markopoulou
Oct 29, 2000·Trends in Neurosciences·F CalonP J Bédard
Oct 29, 2000·Trends in Neurosciences·W OlanowO Rascol
May 24, 2005·Lancet Neurology·Anette Schrag
Aug 26, 2006·Nature Clinical Practice. Neurology·C Warren OlanowFabrizio Stocchi
Oct 24, 2006·Nature Clinical Practice. Neurology·Carlo ColosimoAlfredo Berardelli
Jul 17, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hanna S LindgrenM Angela Cenci
Dec 1, 2006·Pain Practice : the Official Journal of World Institute of Pain·M A Royal
Dec 4, 2003·Clinical Neuropharmacology·Carlo Colosimo, Alessandra Craus
Feb 24, 2001·The Laryngoscope·A Blitzer, L Sulica
Jun 5, 2002·Plastic and Reconstructive Surgery·Bahman GuyuronJanine Davis
May 15, 2007·The Neurologist·Robert A Hauser, Theresa A Zesiewicz
Sep 25, 2003·Plastic and Reconstructive Surgery·Bahman GuyuronJennifer Kriegler
Dec 14, 2011·The Neurologist·Maria Cruz Rodriguez-OrozOriol de Fabregues

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.